Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Supply Chain
July 26, 2020 11:33 AM

Fall, flu season to bring new challenges during pandemic

Adam Bonislawski, 360Dx
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    While it's unclear whether or not the U.S. ever exited the first round of the COVID-19 pandemic, many are already preparing for new infections in the fall that could complicate the typical high season for respiratory viruses.

    The lab industry is likely to face new challenges, foremost among them the continued difficulties around reaching sufficient test capacity and the issue of other respiratory infections like influenza complicating the diagnostic picture.

    "You really have two components of testing that we have to think about," said Nathan Ledeboer, medical director of the microbiology laboratory at the Medical College of Wisconsin and Froedtert Hospital. "One, it's about having enough having enough capacity. Then number two, we'll now layer in all the additional respiratory viruses, in particular flu and RSV."

    Given the similarity in terms of symptoms between these respiratory viruses and SARS-CoV-2, multiplexing will be a key consideration, Ledeboer said, noting that at Froedtert he and his colleagues are planning to develop multiplexed assays so they can test for at least flu and SARS-CoV-2 in a single test.

    "That is a major shift in how we test and what we test," he said. "We were really at the tail end of our flu season [when SARS-CoV-2 hit]. And the social distancing that was implemented really knocked off our flu numbers very quickly."

    He noted that when pandemic-driven social distancing started, his lab was seeing around a 25% positivity rate for flu, which dropped to around 1% over the next two weeks.

    The coming flu season combined with the SARS-CoV-2 outbreak will likely put further pressure on molecular testing capacities for both diseases, Ledeboer said.

    "In starting to engage with our vendors [about the fall] they are basically telling us, yeah, we'll be able to supply you with flu tests at the same level we did last year," he said. However, he added, last year his lab ran only around 600 flu tests per week, while it currently runs around 1,500 to 2,000 SARS-CoV-2 tests per day. Multiplexing the two together won't be possible if the lab's flu testing supplies remain the same as the year before, Ledeboer noted.

    "That's a huge problem, and nobody has really started to think that through yet," he said.

    The reopening of hospitals for more routine care also complicates the situation, Ledeboer said.

    "We support very, very large immunocompromised populations, and in those populations, we are very interested in the broader respiratory virus panels, because we isolate differently for those patients," he said.

    For instance, he said, if an immunocompromised patient had respiratory syncytial virus (RSV) the hospital would treat that patient with the antiviral drug ribavirin. Being able to specifically determine what respiratory virus a vulnerable patient has is likely to influence treatment.

    This raises the question of what access will look like this fall to broader respiratory virus panels, Ledeboer said.

    To address these issues, he said his lab aims to expand the number of infectious agents it tests for while diversifying its testing supply chain to help avoid shortages.

    "It's hard to predict whether flu will be bad [this year] or what the clinical implications may be," said Robert Boorstein, medical director at Brooklyn-based Lenco Diagnostic Laboratory. "But labs have to be prepared for physicians who are trying to sort out if something is the flu or coronavirus."

    At the same time, he noted, labs are still working to manage COVID-19 testing while also working to bring their more routine testing levels back up to baseline.

    "It's a complex environment," he said. "I think most laboratories will probably have flu-coronavirus testing options, but it will be a matter of reimbursement and ordering patterns that affect how they get used."

    Boorstein said that most manufacturers of syndromic respiratory panels have testing that covers flu and SARS-CoV-2. Additionally, he noted, combination COVID-19 tests are coming online. The Centers for Disease Control and Prevention this month received approval for a molecular SARS-CoV-2-flu test. Molecular diagnostic company Cepheid plans to launch a rapid 4-in-1 test for detection of the coronavirus, flu A, flu B, and respiratory syncytial virus from a single patient sample in Q3 of this year, and Roche said it will launch in the coming months a multiplex test for detecting SARS-CoV-2, flu A, and flu B.

    "I think it will be interesting in terms of reimbursement and algorithms," Boorstein said. "Will insurers reimburse two tests upfront? Will they ask you to do them in some order? Would it be better to do flu first and then COVID, COVID first and then flu? If the flu is positive, will you not get reimbursed for a COVID test? I think all of those are questions that will be asked."

    He said that while his lab has done fairly high volumes of syndromic panels during the last few flu seasons, "there hasn't been a lot of clarity around the use of syndromic panels with COVID, and I think people are reluctant to order a lot of them because they are afraid that there will be insurer pushback."

    In response to questions about potential challenges of SARS-CoV-2 amidst a wave this fall, Pattie Kushner, chief communications officer for LabCorp, said the company is "aware of the potential convergence of flu testing on top of COVID testing, and [is] putting plans in place to address the demand for both tests, including utilizing various testing methodologies and platforms to manage potential volumes."

    Quest Diagnostics spokesperson Kim Gorode said the company is planning for surges in respiratory viruses. "We plan to align with CDC guidance by offering panels that test for both respiratory viruses and COVID-19 through a range of platforms, in addition to offering a variety of options for flu and COVID-19 testing, separately."

    Capacity remains a major issue, of course, and will almost certainly still be a challenge in the fall when testing for employees returning to the workforce and students going back to school could spike demand even higher. The lab industry is already struggling to keep up with the demand generated by the current spike in SARS-CoV-2 infections.

    Last week, LabCorp said that its average turnaround time for SARS-CoV-2 tests was between three and five days while Quest said this week that its average turnaround time for high-priority patients was now more than two days, and for non-priority patients, the turnaround time was seven days or more.

    The company also indicated that it was working to tamp down the flow of incoming COVID test orders, noting that "the inflow of specimens to our labs has stabilized … due to our efforts to modulate orders for low risk patients."

    In a recent interview with the Financial Times, James Davis, executive vice president at Quest said that PCR testing capacities would not be able to grow enough in coming months to meet anticipated demand.

    On a conference call following the release of Quest's second quarter financial results on Thursday, Steve Rusckowski, the company's chairman, CEO, and president, said that while the company expects to expand its SARS-CoV-2 molecular testing capacity from 130,000 tests per day to 150,000 per day in the next several weeks and to continue to build capacity in the months ahead, it was constrained by a number of factors, including access to instrumentation, reagents, and manpower.

    He said the company was exploring a range of options to further boost testing capacity and highlighted the company's federal approval last week for pooled SARS-CoV-2 testing.

    Rapid antigen testing could help close the gap. Last week, HHS officials said they were shipping instrumentation and tests for rapid point-of-care antigen testing to nursing homes in areas with high levels of COVID infection.

    This story first appeared in our sister publication, 360Dx,which provides in-depth coverage of in vitro diagnostics and the clinical lab market.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    366418029.jpg
    Pfizer plant in North Carolina restarts production after tornado damage
    366418029.jpg
    Damage to Pfizer plant highlights vulnerable supply chain
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Daily Dose Newsletter: Sign up to receive a late afternoon weekday roundup of that day’s breaking news and developments in healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing